Breaking News, Trials & Filings

J&JPRD Gets Complete Response Letter for Ceftobiprole

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) received a Complete Response letter from the FDA for ceftobiprole.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) received a Complete Response letter from the FDA for ceftobiprole. The NDA was originally submitted in May 2007 for the treatment of complicated skin and skin structure infections (cSSSI), including diabetic foot infections. The FDA has requested additional information and recommended additional studies be conducted in order to consider a future approval of ceftobiprole in this indication. Ceftobiprole wa...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters